Author information:
(1)Milner Therapeutics Institute, University of Cambridge, Cambridge, UK.
(2)Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, 
UK.
(3)Storm Therapeutics Ltd, Cambridge, UK.
(4)Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, 
Cambridge, UK.
(5)Evotec (UK) Ltd, Abingdon, UK.
(6)The Center for the Study of Hematological Malignancies/Karaiskakio 
Foundation, Nicosia, Cyprus.
(7)Division of Virology, Department of Pathology, University of Cambridge, 
Cambridge, UK.
(8)MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, 
Cambridge, UK.
(9)The Gurdon Institute and Department of Pathology, University of Cambridge, 
Cambridge, UK.
(10)Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum 
München, German Research Center for Environmental Health (HMGU), Munich, 
Germany.
(11)German Consortium for Translational Cancer Research (DKTK), Munich, Germany.
(12)Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig 
Maximilians University München, Munich, Germany.
(13)Storm Therapeutics Ltd, Cambridge, UK. oliver.rausch@stormtherapeutics.com.
(14)Milner Therapeutics Institute, University of Cambridge, Cambridge, UK. 
kt404@cam.ac.uk.
(15)Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, 
UK. kt404@cam.ac.uk.
(16)Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, 
Cambridge, UK. kt404@cam.ac.uk.
(17)The Gurdon Institute and Department of Pathology, University of Cambridge, 
Cambridge, UK. kt404@cam.ac.uk.
(18)Milner Therapeutics Institute, University of Cambridge, Cambridge, UK. 
t.kouzarides@gurdon.cam.ac.uk.
(19)The Gurdon Institute and Department of Pathology, University of Cambridge, 
Cambridge, UK. t.kouzarides@gurdon.cam.ac.uk.
(#)Contributed equally